Background When heart failure with reduced ejection fraction (HFrEF) and chronic kidney
disease (CKD) co-exist, Renin angiotensin-aldosterone system inhibitors (RAASi) are often …

Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes
in patients who have heart failure with reduced ejection fraction (HFrEF). To reduce mortality …

Renal function is often affected in patients with chronic heart failure with reduced ejection
fraction (HFrEF). The complex interplay between heart and renal dysfunction makes renal …

Introduction: Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor
blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid …

Inhibitors of the renin–angiotensin–aldosterone (RAAS) system are cornerstones of the
management of patients with heart failure with reduced left ventricular ejection fraction …

Objectives: The aim of this study was to determine whether telmisartan decreases all-cause
and cardiovascular mortality and morbidity in hemodialysis patients with chronic heart failure …

Patients with heart failure (HF) and reduced ejection fraction (HFREF) are at increased risk
of death and hospitalizations for HF. Numerous registries have reported a large and …

Abstract Introduction and Objectives Renin-angiotensin-aldosterone system inhibitors
(RAASi) are the cornerstone of treatment of heart failure with reduced ejection fraction …

Aims We evaluated the effect of (dual) renin–angiotensin–aldosterone system (RAAS)
blockade with valsartan and an ACE inhibitor [92.7% of patients were treated with an ACE …

Background—Renin–angiotensin aldosterone system (RAAS) inhibitors significantly
improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF) …